After Can-Fite BioPharma announced earlier today that top line efficacy results are now expected during the first quarter of 2019 in its Phase 2 clinical trial of drug candidate Namodenoson for the treatment of advanced hepatocellular carcinoma due to patient survival, H.C. Wainwright analyst Jason Kolbert said he is "cautiously optimistic" given that he finds it surprising that the trial has gone on this long. His understanding is that a six week or bigger difference between the active and control arms is considered clinically meaningful in this indication, adding that if the data is strong enough the trial is could be used as a registrational study given the unmet medical need. He keeps a Buy rating on Can-Fite shares, which were down 5% in morning trading.